HK1052502A1 - Hydrochloride salts of 5-Ä4-Ä2-(N-methyl-n-2-pyridyl) amino) ethoxyÜbenzylÜthiazolidine-2,4-dione - Google Patents

Hydrochloride salts of 5-Ä4-Ä2-(N-methyl-n-2-pyridyl) amino) ethoxyÜbenzylÜthiazolidine-2,4-dione

Info

Publication number
HK1052502A1
HK1052502A1 HK03103374A HK03103374A HK1052502A1 HK 1052502 A1 HK1052502 A1 HK 1052502A1 HK 03103374 A HK03103374 A HK 03103374A HK 03103374 A HK03103374 A HK 03103374A HK 1052502 A1 HK1052502 A1 HK 1052502A1
Authority
HK
Hong Kong
Prior art keywords
ethoxyübenzylüthiazolidine
dione
pyridyl
amino
methyl
Prior art date
Application number
HK03103374A
Other languages
English (en)
Inventor
Andrew Simon Craig
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of HK1052502A1 publication Critical patent/HK1052502A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK03103374A 2000-03-14 2003-05-13 Hydrochloride salts of 5-Ä4-Ä2-(N-methyl-n-2-pyridyl) amino) ethoxyÜbenzylÜthiazolidine-2,4-dione HK1052502A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0006133.3A GB0006133D0 (en) 2000-03-14 2000-03-14 Novel pharmaceutical
PCT/GB2001/001131 WO2001068646A1 (en) 2000-03-14 2001-03-14 Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (1)

Publication Number Publication Date
HK1052502A1 true HK1052502A1 (en) 2003-09-19

Family

ID=9887600

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103374A HK1052502A1 (en) 2000-03-14 2003-05-13 Hydrochloride salts of 5-Ä4-Ä2-(N-methyl-n-2-pyridyl) amino) ethoxyÜbenzylÜthiazolidine-2,4-dione

Country Status (31)

Country Link
US (2) US7074811B2 (xx)
EP (1) EP1265893B1 (xx)
JP (1) JP2003527393A (xx)
KR (1) KR100746813B1 (xx)
CN (1) CN100516062C (xx)
AP (1) AP1545A (xx)
AT (1) ATE302202T1 (xx)
AU (1) AU777987B2 (xx)
BG (1) BG65924B1 (xx)
BR (1) BR0108870A (xx)
CA (1) CA2403109A1 (xx)
CZ (1) CZ20023074A3 (xx)
DE (1) DE60112729T2 (xx)
DK (1) DK1265893T3 (xx)
DZ (1) DZ3316A1 (xx)
EA (1) EA005115B1 (xx)
ES (1) ES2243458T3 (xx)
GB (1) GB0006133D0 (xx)
HK (1) HK1052502A1 (xx)
HU (1) HUP0300158A3 (xx)
IL (2) IL151425A0 (xx)
MA (1) MA25658A1 (xx)
MX (1) MXPA02008972A (xx)
NO (1) NO323448B1 (xx)
NZ (1) NZ520910A (xx)
OA (1) OA12229A (xx)
PL (1) PL357283A1 (xx)
SK (1) SK286399B6 (xx)
UA (1) UA73974C2 (xx)
WO (1) WO2001068646A1 (xx)
ZA (1) ZA200207292B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
DK1448559T3 (da) * 2001-11-21 2007-04-30 Smithkline Beecham Plc 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolodin-2,4-dionbenzensulfat; fremgangsmåde til dets fremstilling; polymorf i, II og III deraf; og dets anvendelse som farmaceutisk aktiv bestenddel
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20060235008A1 (en) 2004-08-19 2006-10-19 Hetero Drugs Limited Novel polymorphs of efavirenz
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN107235980A (zh) 2006-05-04 2017-10-10 勃林格殷格翰国际有限公司 多晶型
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
ES2953123T3 (es) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Terapia para la diabetes
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US137940A (en) * 1873-04-15 Improvement in elevators
US120078A (en) * 1871-10-17 Improvement in revolving flower-stands
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9413975D0 (en) * 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
IL133142A0 (en) 1997-06-18 2001-03-19 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
US6664278B2 (en) * 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9909041D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909075D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
EP1277753A1 (en) 1999-04-23 2003-01-22 SmithKline Beecham plc Thiazolidinedione derivative and its use as antidiabetic
YU75301A (sh) 1999-04-23 2004-07-15 Smithkline Beecham P.L.C. Polimorfni oblik soli maleinske kiseline i 5-(4-(2-(n-metil- n-(2-piridil)amino)etoksi)benzil)-tiazolidin-2,4-diona
RS50114B (sr) 1999-04-23 2009-03-25 Smithkline Beecham P.L.C., Novi polimorfni oblik 5-/4-/2-(n-metil- n-(2-piridil)amino/ etoksi/benzil/ tiazolidin-2,4-dion, soli maleinske kiseline
HU225919B1 (en) 1999-12-18 2007-12-28 Richter Gedeon Nyrt Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
CN1277965A (zh) 2000-06-14 2000-12-27 中国医药研究开发中心 盐酸罗格列酮及其应用
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical

Also Published As

Publication number Publication date
BG107012A (bg) 2003-04-30
SK13302002A3 (sk) 2003-02-04
MXPA02008972A (es) 2003-02-10
DZ3316A1 (fr) 2001-09-20
DE60112729D1 (de) 2005-09-22
AU777987B2 (en) 2004-11-11
NO323448B1 (no) 2007-05-07
DE60112729T2 (de) 2006-06-08
EP1265893B1 (en) 2005-08-17
SK286399B6 (sk) 2008-09-05
KR20020079998A (ko) 2002-10-21
CA2403109A1 (en) 2001-09-20
MA25658A1 (fr) 2002-12-31
WO2001068646A1 (en) 2001-09-20
AP1545A (en) 2006-01-12
BG65924B1 (bg) 2010-05-31
DK1265893T3 (da) 2005-11-14
ZA200207292B (en) 2003-05-06
BR0108870A (pt) 2002-12-17
UA73974C2 (en) 2005-10-17
US20040152901A1 (en) 2004-08-05
CN1358184A (zh) 2002-07-10
CZ20023074A3 (cs) 2003-02-12
AU4084301A (en) 2001-09-24
HUP0300158A3 (en) 2005-04-28
NZ520910A (en) 2004-06-25
IL151425A0 (en) 2003-04-10
EA005115B1 (ru) 2004-10-28
JP2003527393A (ja) 2003-09-16
EP1265893A1 (en) 2002-12-18
HUP0300158A2 (en) 2003-05-28
NO20024307L (no) 2002-09-09
KR100746813B1 (ko) 2007-08-06
US20050267162A1 (en) 2005-12-01
PL357283A1 (en) 2004-07-26
AP2002002600A0 (en) 2002-09-30
IL151425A (en) 2009-08-03
GB0006133D0 (en) 2000-05-03
CN100516062C (zh) 2009-07-22
OA12229A (en) 2003-11-07
NO20024307D0 (no) 2002-09-09
EA200200975A1 (ru) 2003-02-27
US7074811B2 (en) 2006-07-11
ATE302202T1 (de) 2005-09-15
ES2243458T3 (es) 2005-12-01

Similar Documents

Publication Publication Date Title
HK1052502A1 (en) Hydrochloride salts of 5-Ä4-Ä2-(N-methyl-n-2-pyridyl) amino) ethoxyÜbenzylÜthiazolidine-2,4-dione
MXPA03006260A (es) Derivados de amina sustituidos y metodos de uso.
IL150406A0 (en) Dipeptide nitrile cathepsin k inhibitors
AU2001234484A1 (en) Amide compounds for inhibiting protein kinases
AU2001280187A1 (en) Cyclic amine derivatives
IL159926A0 (en) Aminoisoxazole derivatives active as kinase inhibitors
ZA200204397B (en) Nitrile derivatives as cathepsin K inhibitors.
EP1445249A4 (en) NOVEL BENZOPHENONE DERIVATIVES OR SALTS THEREOF
DK1218383T3 (da) Biocykliske imidazo-5-yl-aminoderivater
HK1057539A1 (en) Beta-amino acid nitrile derivatives
AU2002337749A1 (en) Pioglitazone hydrochloride
IL152352A0 (en) Salts of bicyclic, n-acylated imidazo-3-amines and imidazo-5-amines
AU2001258305A1 (en) Salts of bicyclic, N-acylated imidazo-3-amines and imidazo-5-amines
HK1057749A1 (en) The hydrochloride salt of 5Ä4-Ä2-(n-methyl-n-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione
AU5029801A (en) Copolymers of allylphosphonium salts
ZA200206140B (en) Heterocyclic amide Derivatives.
AU5404500A (en) Reductive amination of aldehydes
AP2003002767A0 (en) Sodium salts of 5-Ä4-Ä2-(N-methyl-N-(2-pyridyl) amino) ethoxyÜ benzylÜ thazolidine-i, 4-dione
CN1093143C (zh) 高聚氨基复合物
HU0401377D0 (en) N-(3-butin-1-yl)-n-hydroxy-urea compound
AU2003243605A8 (en) 3-'2-(dimethylamino) ethyl
ZA200305198B (en) Substituted amine derivatives and methods of use.
AU2001280112A1 (en) Amine derivatives
GB0129352D0 (en) Timing etc circuitry
AUPQ896500A0 (en) Amino acid derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120314